Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Salmefamol orally in asthmatics - two doses compared

R W Sillett, C H Dash, M W McNicol

    European Journal of Clinical Pharmacology
    |February 6, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A.

    Haemophilia : the official journal of the World Federation of Hemophilia·2011
    Same author

    Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery.

    Haemophilia : the official journal of the World Federation of Hemophilia·2011
    Same author

    Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.

    Clinical and experimental immunology·2010
    Same author

    The effect of Renal Failure and Dialysis on the Pharmacokinetics of Cefuroxime.

    Proceedings of the Royal Society of Medicine·2010
    Same author

    Accidental Hypothermia [Abstract].

    Proceedings of the Royal Society of Medicine·2009
    Same author

    The clearance kinetics of autologous RhD-positive erythrocytes coated ex vivo with novel recombinant and monoclonal anti-D antibodies.

    Clinical and experimental immunology·2007

    Salmefamol effectively improved asthma control, with both 1 mg and 2 mg oral doses significantly enhancing lung function (PEFR and FEV1) for several hours. No significant difference in efficacy was observed between doses, though the higher dose caused a slight blood pressure drop.

    Area of Science:

    • Pharmacology
    • Respiratory Medicine
    • Clinical Trials

    Background:

    • Chronic asthma requires effective bronchodilator therapy.
    • Salmefamol is an oral beta-2 agonist used for asthma management.
    • Understanding dose-response relationships is crucial for optimizing treatment.

    Purpose of the Study:

    • To compare the efficacy and safety of two oral doses of salmefamol (1 mg and 2 mg) in patients with chronic asthma.
    • To evaluate the duration of action for each dose on respiratory parameters.
    • To identify any significant differences in ventilatory capacity and side effects between the doses.

    Main Methods:

    • A double-blind, cross-over study design was employed.
    • Twelve patients with chronic asthma participated in the study.

    Related Experiment Videos

  • Patients received oral salmefamol at 1 mg and 2 mg doses, with measurements of PEFR and FEV1 taken over time.

    • Main Results:

    • Both 1 mg and 2 mg doses of salmefamol increased PEFR and FEV1 by 40-50%.
    • Significant improvements in lung function lasted 3-4 hours, with 20% improvement extending to 4-6 hours.
    • No significant difference in ventilatory capacity was found between the two doses; however, the 2 mg dose caused a statistically significant fall in diastolic blood pressure.

    Conclusions:

    • Oral salmefamol at 1 mg and 2 mg provides significant bronchodilation in chronic asthma patients.
    • The higher dose (2 mg) did not offer superior ventilatory benefits over the 1 mg dose.
    • Potential side effects include a transient decrease in diastolic blood pressure and tremor, with the higher dose showing a greater impact on blood pressure.